Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market Overview

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from the nose, and superficial bleeding into the skin that appears as a rash of pinpoint-sized reddish-purple spots, usually on the lower legs.

The Idiopathic Thrombocytopenic Purpura pipeline drugs market research report provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market Targets

Some of the targets of the Idiopathic Thrombocytopenic Purpura pipeline drugs market are Thrombopoietin Receptor, Tyrosine Protein Kinase SYK, Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and Complement Factor B.

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by targets

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market

Some of the mechanisms of action of the Idiopathic Thrombocytopenic Purpura pipeline drugs market are Thrombopoietin Receptor Agonist, Tyrosine Protein Kinase SYK Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 Replacement, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 Inhibitor, Complement Factor B Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, and Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17.

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by mechanisms of action

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market

The routes of administration in the Idiopathic Thrombocytopenic Purpura pipeline drugs market are subcutaneous, oral, intravenous, and parenteral.

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by routes of administration

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market

The molecule types in the Idiopathic Thrombocytopenic Purpura pipeline drugs market are small molecule, fusion protein, monoclonal antibody, recombinant protein, antibody, gene-modified cell therapy, gene therapy, polysaccharide, and recombinant enzyme.

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by molecule types

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key Idiopathic Thrombocytopenic Purpura Pipeline Drugs Market Companies

Some of the key companies in the Idiopathic Thrombocytopenic Purpura pipeline drugs market are 3SBio Inc, Amgen Inc, Biotest AG, GC Pharma, HanAll Biopharma Co Ltd, Hutchison MediPharma Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Rigel Pharmaceuticals Inc, and Swedish Orphan Biovitrum AB.

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by key companies

Idiopathic Thrombocytopenic Purpura pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Thrombopoietin Receptor, Tyrosine Protein Kinase SYK, Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and Complement Factor B
Mechanisms of Action Thrombopoietin Receptor Agonist, Tyrosine Protein Kinase SYK Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 Replacement, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 Inhibitor, Complement Factor B Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, and Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17
Routes of Administration Subcutaneous, Oral, Intravenous, and Parenteral
Molecule Types Small Molecule, Fusion Protein, Monoclonal Antibody, Recombinant Protein, Antibody, Gene-Modified Cell Therapy, Gene Therapy, Polysaccharide, and Recombinant Enzyme
Key Companies 3SBio Inc, Amgen Inc, Biotest AG, GC Pharma, HanAll Biopharma Co Ltd, Hutchison MediPharma Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Rigel Pharmaceuticals Inc, and Swedish Orphan Biovitrum AB

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • Reviews of pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3SBio Inc
Amgen Inc
Argenx SE
BeiGene Ltd
Beijing Tide Pharmaceutical Co Ltd
Biogen Inc
Biotest AG
BioXpress Therapeutics SA
Clover Biopharmaceuticals Ltd
Cour Pharmaceuticals Development Co Inc
GC Pharma
Generium
Genosco Inc
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Hutchison MediPharma Ltd
Iltoo Pharma
InnoCare Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
KM Biologics Co Ltd
Novartis AG
Oak Hill Bio Inc
Pfizer Inc
Pharmagenesis Inc
Pharmapraxis
PlateletBio
Principia Biopharma Inc
Qilu Pharmaceutical Co Ltd
Rigel Pharmaceuticals Inc
Shandong Quangang Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Simcere Pharmaceutical Group Ltd
Swedish Orphan Biovitrum AB
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
UCB SA
Zhejiang Hisun Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drug Profiles

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Product Development Milestones

Featured News & Press Releases

Jul 23, 2021: Borui’s new drug Zebetuzumab injection have been approved for clinical trials

Jul 14, 2021: New TAVALISSE data analyses to be presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Jun 29, 2021: Hengrui Pharmaceutical provides double guarantee of efficacy and safety for ITP treatment

Jun 01, 2021: Sobi at EHA virtual congress 2021: focus on use Doptelet (avatrombopag) in chronic immune thrombocytopenia

May 28, 2021: The application for clinical trial of Zuberitamab biological product of Borui biotechnology have been accepted successively

May 12, 2021: New data on rilzabrutinib to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders

Mar 12, 2021: First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children

Jun 13, 2019: Rigel to present two posters highlighting Fostamatinib at the 24th Congress of the European Hematology Association

May 16, 2019: Rigel enrolls first patient in phase 3 clinical trial of Fostamatinib Disodium Hexahydrate in warm autoimmune hemolytic anemia

Feb 11, 2019: Scottish Medicine Consortium, following an abbreviated submission has accepted romiplostim (Nplate) for restricted use within NHSScotland

Dec 03, 2018: argenx provides detailed data from phase 2 clinical trial of efgartigimod in immune thrombocytopenia

Dec 02, 2018: Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies

Oct 19, 2018: Principia Biopharma announces PRN1008 receives orphan-drug designation from FDA for treatment of immune thrombocytopenic purpura

Jul 31, 2018: Kyowa Hakko Kirin submits application for additional indication for Romiplostim (Recombinant) for aplastic anemia in Japan

Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by 3SBio Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Amgen Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Argenx SE, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by BeiGene Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Biogen Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Biotest AG, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by BioXpress Therapeutics SA, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Clover Biopharmaceuticals Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Cour Pharmaceuticals Development Co Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by GC Pharma, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Generium, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genosco Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by GlaxoSmithKline Plc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by HanAll Biopharma Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Hutchison MediPharma Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Iltoo Pharma, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by InnoCare Pharma Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by KM Biologics Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Novartis AG, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Oak Hill Bio Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pfizer Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pharmagenesis Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pharmapraxis, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by PlateletBio, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Principia Biopharma Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Rigel Pharmaceuticals Inc, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Shandong Quangang Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Swedish Orphan Biovitrum AB, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Taiho Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by UCB SA, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, 2022

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, 2022 (Contd..1)

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.